GAO: Medicare’s Opioid Use Monitoring Lets At-Risk Patients Fall Through the Cracks

Drug Industry Daily
A A
The federal government’s guidance for monitoring opioid use among Medicare beneficiaries does not go far enough in identifying which beneficiaries are most at risk and the Centers for Medicare & Medicaid Services should collect data on exactly how many at-risk beneficiaries receive high doses, according to a new GAO report.

To View This Article:

Login

Subscribe To Drug Industry Daily